earnings
confidence high
sentiment negative
materiality 0.60
Eloxx Q1 net loss narrows to $6.2M; cash runway into Q3 2023
Eloxx Pharmaceuticals, Inc.
2023-Q1 EPS
reported -$2.88
vs consensus -$2.60
▼ miss
(-10.7%)
- Net loss of $6.2M ($2.88/sh) vs $11.6M ($5.36/sh) in Q1 2022; R&D and G&A expenses decreased.
- Cash and equivalents $4.9M at March 31; amended Hercules loan reduced minimum cash to $2.25M, interest-only until Sep 1, 2023.
- Current cash expected to fund operations into Q3 2023, assuming Phase 3 activities start in Q3.
- Topline data for ELX-02 in Alport syndrome (including biopsy) expected H1 2023; meaningful protein reduction seen in one patient.
- FDA cleared ZKN-013 SAD trial for RDEB; preclinical showed up to 18-fold increase in full-length COL VII protein.